HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Harmonized Probiotic Labeling In Europe? Not Before 2027, Says EC Expert Advisor

Executive Summary

The European Commission is unlikely to address the diverging regulatory approaches to probiotic labeling across the EU during its current term, pointed out an expert advisor in a recent webinar. Even if the next Commission addresses the issue early on, it will still be at least four years before implementation of any changes, and this is an “optimistic view,” commented Fit for Future Platform stakeholder group member Lasse Hamilton Heidemann.

You may also be interested in...



France Becomes Latest EU Member To Allow 'Probiotic' Label For Dietary Supplements

Thanks to work led by consumer healthcare industry association NèreS, France now allows the term “probiotic” on the label of dietary supplements that meet certain conditions, as well as the related health claim “contributes to the balance of the intestinal flora.” The country joins a growing movement away from the European Commission's restrictions on the use of the term.

Stada’s Natures Aid Expands UK Children’s Wellness Lines

Stada Arzneimittel’s UK dietary supplement subsidiary Natures Aid is expanding its Mini Drops and Super Stars children’s wellness brands with new products.

Longer Exclusivity Periods For EU Centralized Rx-To-OTC Switches? Commission Says No

One way to revitalize interest in the EU's centralized switch procedure would be to introduce longer data exclusivity periods or market exclusivity for successful applicants, concluded an AESGP expert switch panel presenting at the association's 59th Annual Meeting in Paris, France. However, a European Commission representative told another panel that this was not under consideration as part of the EU pharmaceutical legislation revision.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel